Thyroid Diseases: Clinical Trials

33 trials for Thyroid Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

33 terminated. 33 Phase 2, 7 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 233Terminated 33
Phase 17Terminated 7
Phase 31Terminated 1

Follow Thyroid Diseases: new trials by email Literature Review of Thyroid Diseases trials Research Report on Thyroid Diseases

Trials (filtered) newest first · largest first

All 33 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
AMXT1501, DFMO - Cancer, Solid Tumor
Phase 1 / Phase 2TerminatedAminex Therapeutics, Inc.152022-11-292024-12-24
3-D Super Resolution Ultrasound Microvascular Imaging
Definity, Acoustic Angiography - Breast Cancer, Thyroid Cancer
Phase 2TerminatedUNC Lineberger Comprehensive Cancer Center272022-05-262025-10-06
IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
Pembrolizumab - Thyroid
Phase 2TerminatedM.D. Anderson Cancer Center62022-02-112026-03-23
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Tovorafenib - Melanoma, Solid Tumor
Phase 2TerminatedDay One Biopharmaceuticals, Inc.232021-07-152025-10-02
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Alectinib - Neoplasms, Colorectal Neoplasms
Phase 2TerminatedHoffmann-La Roche12021-05-242023-08-07
Anti-VEGF Therapy for Acute Thyroid Eye Disease
Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) alone - Thyroid Eye Disease
Phase 2TerminatedMassachusetts Eye and Ear Infirmary82020-11-022026-10-20
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System
Artificial Tears - Thyroid Carcinoma, Radioactive Iodine Level
Phase 2TerminatedVanderbilt-Ingram Cancer Center92020-10-052024-01-18
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
TPX-0046 - Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1 / Phase 2TerminatedTurning Point Therapeutics, Inc.412019-12-062024-06-13
ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )
RVT-1401 (Administered via subcutaneous injection), Placebo (Administered via subcutaneous injection) - Graves' Ophthalmopathy (GO)
Phase 2TerminatedImmunovant Sciences GmbH652019-07-232022-09-22
Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
Durvalumab, Tremelimumab - Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma
Phase 2TerminatedGrupo Espanol de Tumores Neuroendocrinos792019-04-022026-03-11
Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer
Lenvatinib - Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma
Phase 2TerminatedEmory University42019-01-162022-11-10
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
Lenvatinib, Sorafenib, Cabozantinib - Thyroid Cancer, Thyroid Cancer, Medullary
Phase 2TerminatedH. Lee Moffitt Cancer Center and Research Institute62018-08-062021-07-14
Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer
Gallium Ga 68-labeled PSMA-11, Magnetic Resonance Imaging, Positron Emission Tomography (PET) - Thyroid Gland Carcinoma
Phase 2TerminatedUniversity of California, San Francisco122018-03-192021-06-29
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
ETBX-011, ALT-803 - Thyroid Cancer, Colon Cancer
Phase 1 / Phase 2TerminatedNantCell, Inc.32017-06-262024-08-06
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Alectinib - ALK-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Non-small Cell Lung Cancer (NSCLC)
Phase 1 / Phase 2TerminatedDana-Farber Cancer Institute52017-06-192021-09-27
Celecoxib for Thyroid Eye Disease
Celecoxib, artificial tears - Thyroid Eye Disease
Phase 2TerminatedJohns Hopkins University72017-03-052020-07-31
Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers
Metformin Hydrochloride, Radioactive Iodine, Placebo - Thyroid
Phase 2TerminatedSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University132017-01-052025-12-11
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
CUDC-907 - Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer
Phase 2TerminatedNational Cancer Institute (NCI)72016-12-222018-12-21
Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study
gemcitabine -oxaliplatine combination - Thyroid Cancer
Phase 2TerminatedAssistance Publique - Hôpitaux de Paris212016-04-072019-03-18
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
eFT508 - Cancer
Phase 1 / Phase 2TerminatedEffector Therapeutics662015-12-032020-11-02

Showing 20 of 33. Sign in to see all of them.

Narrower conditions

Thyroid Neoplasms (22)  ·  Carcinoma, Medullary (6)  ·  Thyroid Cancer, Papillary (6)  ·  Carcinoma, Non-Small-Cell Lung (5)  ·  Graves Ophthalmopathy (5)  ·  Thyroid Carcinoma, Anaplastic (5)  ·  Breast Neoplasms (4)  ·  Melanoma (4)  ·  Neoplasms (4)  ·  Adenocarcinoma, Follicular (3)  ·  Colorectal Neoplasms (3)  ·  Head and Neck Neoplasms (3)  ·  Neoplasm Metastasis (3)  ·  Ovarian Neoplasms (3)

Broader conditions

Endocrine System Diseases (33)  ·  Endocrine Gland Neoplasms (25)  ·  Neoplasms by Site (25)  ·  Head and Neck Neoplasms (22)  ·  Neoplasms (22)  ·  Neoplasms by Histologic Type (18)  ·  Neoplasms, Glandular and Epithelial (17)  ·  Carcinoma (15)  ·  Adenocarcinoma (11)  ·  Neoplasms, Germ Cell and Embryonal (10)  ·  Neoplasms, Nerve Tissue (10)  ·  Neuroectodermal Tumors (10)  ·  Neuroendocrine Tumors (9)  ·  Immune System Diseases (7)

Interventions

Imatinib Mesylate (2)  ·  Lubricant Eye Drops (2)  ·  Sorafenib (2)  ·  alectinib (2)  ·  lenvatinib (2)  ·  vandetanib (2)  ·  ALT-803 (1)  ·  Bevacizumab (1)  ·  Bortezomib (1)  ·  CUDC-907 (1)  ·  Capecitabine (1)  ·  Carboplatin (1)  ·  Celecoxib (1)  ·  Dacarbazine (1)  ·  Doxepin (1)

Sponsors

National Cancer Institute (NCI) (4)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  M.D. Anderson Cancer Center (2)  ·  Aminex Therapeutics, Inc. (1)  ·  Dana-Farber Cancer Institute (1)  ·  Day One Biopharmaceuticals, Inc. (1)  ·  Effector Therapeutics (1)  ·  Emory University (1)  ·  GlaxoSmithKline (1)  ·  Grupo Espanol de Tumores Neuroendocrinos (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Hoffmann-La Roche (1)  ·  Immunovant Sciences GmbH (1)  ·  Ipsen (1)  ·  Johns Hopkins University (1)

Countries

United States (27)  ·  Spain (4)  ·  France (3)  ·  Australia (2)  ·  Canada (2)  ·  Italy (2)  ·  South Korea (2)  ·  United Kingdom (2)  ·  Belarus (1)  ·  Belgium (1)  ·  Bulgaria (1)  ·  Egypt (1)  ·  Germany (1)  ·  India (1)  ·  Israel (1)

Top investigators

Naris Nilubol, M.D. (2)  ·  Arlene A. Forastiere, MD (1)  ·  Christine H. Chung, M.D. (1)  ·  Francis P Worden, MD (1)  ·  James Gulley, M.D. (1)  ·  James Yao, MD (1)  ·  Jan Tennvall, MD, PhD (1)  ·  Jaume Capdevila, M.D., Ph.D. (1)  ·  Jeremy Barton, MD (1)  ·  Joseph Curry, MD (1)

Results publications

PMID 23113752, PMID 25086465, PMID 30297385, PMID 37816266, PMID 37917111, PMID 41935063, PMID 42826365

NIH funding

2004 (1), 2009 (1), 2018 (1), P30CA006973 (1), P30CA015083 (1), P50CA096784 (1), R01CA220681 (1), U01CA062502 (1)